BRPI0516171A - formas cristalinas de uma pirazol[3,4-c] piridina inibidora do fator xa - Google Patents

formas cristalinas de uma pirazol[3,4-c] piridina inibidora do fator xa

Info

Publication number
BRPI0516171A
BRPI0516171A BRPI0516171-1A BRPI0516171A BRPI0516171A BR PI0516171 A BRPI0516171 A BR PI0516171A BR PI0516171 A BRPI0516171 A BR PI0516171A BR PI0516171 A BRPI0516171 A BR PI0516171A
Authority
BR
Brazil
Prior art keywords
crystalline forms
pyridine
pyrazol
factor
inhibitor
Prior art date
Application number
BRPI0516171-1A
Other languages
English (en)
Inventor
Margaret M Gleeson
Gary Mcgeorge
Bang-Chi Chen
Huiping Zhang
Mary F Malley
John D Dimarco
Denette K Murphy
Xiaotian S Yin
Steven R Fabian
Jasmine M Gupta
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36100111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0516171(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0516171A publication Critical patent/BRPI0516171A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

FORMAS CRISTALINAS DE UMA PIRAZOL¢3,4-C! PIRIDINA INIBIDORA DO FATOR XA. A presente invenção refere-se a formas cristalinas de 1-(3-cloro-fenil)-7-oxo-6-¢4-(2-oxo-1 (2H)piridinil)fenil!-4,5,6,7-tetraidro-1H-pirazol¢3,4-c!-piridina-3-carbox amida e seus solvatos; processos para a produção dessas formas cristalinas; composições farmacêuticas compreendendo essas formas cristalinas; e métodos de tratamento de distúrbios tromboembólicos com essas formas cristalinas ou essas composições farmacêuticas.
BRPI0516171-1A 2004-09-28 2005-09-27 formas cristalinas de uma pirazol[3,4-c] piridina inibidora do fator xa BRPI0516171A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61365604P 2004-09-28 2004-09-28
US11/235,519 US7388096B2 (en) 2004-09-28 2005-09-26 Crystalline forms of a factor Xa inhibitor
PCT/US2005/034512 WO2006036927A1 (en) 2004-09-28 2005-09-27 Crytalline forms of a pyrazolo `3, 4-c ! pyridine factor xa inhibitor

Publications (1)

Publication Number Publication Date
BRPI0516171A true BRPI0516171A (pt) 2008-08-26

Family

ID=36100111

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516171-1A BRPI0516171A (pt) 2004-09-28 2005-09-27 formas cristalinas de uma pirazol[3,4-c] piridina inibidora do fator xa

Country Status (12)

Country Link
US (1) US7388096B2 (pt)
EP (1) EP1819703A1 (pt)
JP (1) JP2008514711A (pt)
KR (1) KR20070067108A (pt)
AU (1) AU2005289599A1 (pt)
BR (1) BRPI0516171A (pt)
CA (1) CA2582223A1 (pt)
IL (1) IL182148A0 (pt)
MX (1) MX2007003426A (pt)
NO (1) NO20071653L (pt)
RU (1) RU2007115859A (pt)
WO (1) WO2006036927A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304157B2 (en) 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
BRPI0519331A2 (pt) 2004-12-15 2009-01-20 Bristol Myers Squibb Co formas cristalina de um inibidor de fator xa
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
CA2959987C (en) * 2014-09-02 2023-05-09 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Pyrazolo[3,4-c]pyridine compounds and their anti-thrombosis effect

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CN104744461A (zh) 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Also Published As

Publication number Publication date
IL182148A0 (en) 2007-07-24
CA2582223A1 (en) 2006-04-06
NO20071653L (no) 2007-03-30
RU2007115859A (ru) 2008-11-10
JP2008514711A (ja) 2008-05-08
US20060069118A1 (en) 2006-03-30
MX2007003426A (es) 2007-05-10
EP1819703A1 (en) 2007-08-22
AU2005289599A1 (en) 2006-04-06
WO2006036927A1 (en) 2006-04-06
US7388096B2 (en) 2008-06-17
KR20070067108A (ko) 2007-06-27

Similar Documents

Publication Publication Date Title
NO20074959L (no) Substituerte pyridinderivater
ATE407938T1 (de) Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
NO20050828L (no) lndol-3-svovelderivater
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
MY148809A (en) Crystals of 1,2-dihydropyridine compound and their production process
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20060688L (no) Fusjonerte aryl- og heteroarylderivater som modulatorer av metabolisme og profylakse og behandling av lidelser relatert til dette
WO2007143434A3 (en) Indazole and isoindole derivatives as glucokinase activating agents
NO20055219L (no) Nye forbindelser
NO20076054L (no) Imidiazo - og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20063647L (no) Nye inhibitorer av chymase
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
MY140903A (en) Imidazole derivatives used as tafia inhibitors
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
WO2006028963A3 (en) Substituted heterocyclic compounds and uses thereof
MX2008001538A (es) Aril piridinas y metodos para su uso.
MX2007002525A (es) Compuestos de difeniletileno y usos de los mismos.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]